All Stories

  1. Rethinking How We Provide Guidance When Evidence is Limited
  2. Real-World Comparison of Intravenous vs. Oral Antimicrobial Therapy for Bone and Joint Infections
  3. Methodological quality assessment tool for observational studies comparing treatment effectiveness in infectious diseases: a Delphi consensus and application to studies on bloodstream infections due to carbapenem-resistant Enterobacterales
  4. Infectious Diseases Society of America (IDSA) Position Statement: Why IDSA Did Not Endorse the Community-Acquired Pneumonia Guidelines 2025 Update
  5. P-846. Impact of an Ambulatory Antimicrobial Stewardship Intervention on Respiratory Antibiotic Prescribing in Primary Care Clinics
  6. P-802. Assessing the Benefit of Adding a Rapid Antibiotic Susceptibility Platform for Bloodstream Infections to a Well-Established Stewardship Program within an Academic Health-system
  7. Necrotizing soft-tissue infections survival guide in adult patients: A position statement by the Global Alliance for Infections in Surgery
  8. Infectious Diseases Society of America (IDSA) Position Statement: Why IDSA Did Not Endorse the Community-Acquired Pneumonia Guidelines 2025 Update
  9. Global health at crossroads: uniting together to overcome challenges, restore trust and advance priorities for a sustainable future
  10. Implementation of a pilot program of interprofessional education in infection prevention
  11. AAOS Clinical Practice Guideline Summary Prevention of Total Hip and Knee Arthroplasty Periprosthetic Joint Infection in Patients Undergoing Dental Procedures
  12. The New Reality of Infective Endocarditis: Changes in Patient Demographics and Outcomes in South Carolina
  13. Association Between Reporting Antimicrobial Use and Clostridioides difficile Standardized Infection Ratios in South Carolina Hospitals
  14. P-877. Effectiveness of Oral Step-down Antibiotic Therapy in Uncomplicated Enterococcus faecalis Bloodstream Infection
  15. Appropriateness of ambulatory antibiotic prescribing in South Carolina, 2012–2017
  16. Oral switch antibiotic therapy in uncomplicated Enterococcus faecalis bloodstream infection
  17. Missed Opportunities for Early De-Escalation of Antipseudomonal Beta-Lactam Antimicrobial Therapy in Enterobacterales Bloodstream Infection
  18. WHO global research priorities for antimicrobial resistance in human health
  19. Understanding the Impact of Narrow Spectrum Beta-Lactam Use on Overall and Broad-Spectrum Antimicrobial Utilization in South Carolina
  20. Implementing an Antimicrobial Stewardship Lecture Series for Family Medicine Residency Programs in South Carolina
  21. Incidence and predictors of complications in Gram-negative bloodstream infection
  22. Evaluation of the diagnostic utility of metagenomic next-generation sequencing testing for pathogen identification in infected hosts: a retrospective cohort study
  23. The prevalence of gram-negative bacteria with difficult-to-treat resistance and utilization of novel β-lactam antibiotics in the southeastern United States
  24. 750. Launching the South Carolina Regional Infection Prevention Training (SCRIPT) Center: A Pilot in Interprofessional Education
  25. 2763. Evaluating the Safety and Effectiveness of Long-term Antibiotic Suppression in Patients with Left Ventricular Assist Devices
  26. 2399. Changing Demographics of Infective Endocarditis in South Carolina: An Ecological Study
  27. Application of Precision Medicine Concepts in Ambulatory Antibiotic Management of Acute Pyelonephritis
  28. Ten golden rules for optimal antibiotic use in hospital settings: the WARNING call to action
  29. Interventions in the management of diabetes‐related foot infections: A systematic review
  30. IWGDF/IDSA Guidelines on the Diagnosis and Treatment of Diabetes-related Foot Infections (IWGDF/IDSA 2023)
  31. IWGDF/IDSA guidelines on the diagnosis and treatment of diabetes‐related foot infections (IWGDF/IDSA 2023)
  32. Diagnosis of infection in the foot of patients with diabetes: A systematic review
  33. Intravenous versus Partial Oral Antibiotic Therapy in the Treatment of Uncomplicated Bloodstream Infection Due to Streptococcus Species
  34. Optimization of Empirical Antimicrobial Therapy in Enterobacterales Bloodstream Infection Using the Extended-Spectrum Beta-Lactamase Prediction Score
  35. Cefazolin in the treatment of central nervous system infections: A narrative review and recommendation
  36. Ecologic analysis of antimicrobial use in South Carolina hospitals during 2020–2022
  37. Epidemiology, Outcomes and Tolerability of Protracted Treatment of Nontuberculous Mycobacterial Infections at a Community Teaching Hospital in the Southeastern United States
  38. Paradoxical outcomes of gram‐negative bloodstream infection in solid organ transplant recipients
  39. The progression of sepsis from physiologic systemic inflammatory response to immune dysregulation due to life-threatening infections
  40. Weighing the odds of Bloodstream Infection. What is the Perfect Model to Predict this Risk?
  41. Temporal Association between Influenza Vaccination Coverage and Ambulatory Antibiotic Use in Children
  42. It is time to define an organizational model for the prevention and management of infections along the surgical pathway: a worldwide cross-sectional survey
  43. Evaluation of early clinical failure criteria in Enterococcus species bloodstream infection
  44. Show me the data: A statewide comparative report of National Healthcare Safety Network (NHSN) Antimicrobial Use Option standardized antimicrobial administration ratios (SAARs)
  45. Candida parapsilosis bloodstream infection in an immunocompromised host with discordant multiplex polymerase chain reaction and conventional blood culture results: a case report
  46. Clinical Utility and Cost Effectiveness of Long-Acting Lipoglycopeptides Used in Deep-Seated Infections among Patients with Social and Economic Barriers to Care
  47. Prediction of Mortality in Staphylococcus aureus Bloodstream Infection using Quick Pitt Bacteremia Score
  48. 44. Cost Effectiveness and Clinical Outcomes of Long Acting Lipoglycopeptides Used in Transitions of Care for Deep-Seated Infections
  49. 1298. Validation of Local Pseudomonas aeruginosa Risk Factors in Patients with Community-Onset Bacterial Pneumonia
  50. 1388. Epidemiology and Treatment Outcomes of Nontuberculous Mycobacterial Infections at a Community Teaching Hospital in the Southeastern United States
  51. Change in Antimicrobial Use during COVID-19 Pandemic in South Carolina Hospitals: A Multicenter Observational Cohort Study
  52. A pandemic recap: lessons we have learned
  53. Impact of follow up blood cultures on outcomes of patients with community-onset gram-negative bloodstream infection
  54. Application of Standardized Antimicrobial Administration Ratio as a Motivational Tool within a Multi-Hospital Healthcare System
  55. Novel method of calculating adjusted antibiotic use by microbiological burden
  56. Risk and Clinical Outcomes of Acute Myocardial Infarction and Acute Ischemic Stroke following Gram-Negative Bloodstream Infection
  57. Gram-Negative Bloodstream Infection: Implications of Antimicrobial Resistance on Clinical Outcomes and Therapy
  58. Clostridioides difficile infection and antibiotic prescription rates in the community: Explaining the gender gap
  59. Motivational Application of Standardized Antimicrobial Administration Ratios Within a Healthcare System
  60. 243. Temporal Trends in Appropriateness of Ambulatory Antibiotic Prescribing in South Carolina
  61. 290. Impact of follow up blood cultures on outcomes of patients with gram-negative bloodstream infections
  62. 313. Using a Clinical Decision Prediction Tool to Improve Empirical Antimicrobial Therapy in Ceftriaxone-Resistant Enterobacterales Bloodstream Infections
  63. 955. Addressing Gaps and Disparities in HIV testing in the Emergency Department
  64. Regulatory Approval, Implementation, and Brief Assessment of a Pharmacist- and Pharmacy Trainee-Administered Penicillin Allergy Assessment and Skin Testing Program
  65. Use of Antibiotics in Chronic Obstructive Pulmonary Disease: What is Their Current Role in Older Patients?
  66. Regional and statewide antibiograms as targeted interventions against antibiotic resistance
  67. Temporal trends in ambulatory antibiotic prescription rates in South Carolina: Impact of age, gender, and resident location
  68. Multicenter, Observational Cohort Study Evaluating Third-Generation Cephalosporin Therapy for Bloodstream Infections Secondary to Enterobacter, Serratia, and Citrobacter Species
  69. Pharmacist-Driven Culture and Sexually Transmitted Infection Testing Follow-Up Program in the Emergency Department
  70. Impact of Reappraisal of Fluoroquinolone Minimum Inhibitory Concentration Susceptibility Breakpoints in Gram-Negative Bloodstream Isolates
  71. Gram-Negative Bacteria with Difficult-to-Treat Resistance: A Moving Target
  72. RISK OF ACUTE MYOCARDIAL INFARCTIONS AND ACUTE ISCHEMIC STROKES FOLLOWING GRAM-NEGATIVE BLOODSTREAM INFECTIONS
  73. Evaluating appropriateness and diagnostic stewardship opportunities of multiplex polymerase chain reaction gastrointestinal testing within a hospital system
  74. Empirical Fluoroquinolones versus Broad-Spectrum Beta-Lactams for Gram-Negative Bloodstream Infections in the Absence of Antimicrobial Resistance Risk Factors
  75. Burden of community-associated Clostridioides difficile infection in southeastern United States: a population-based study
  76. Prediction of Sulfamethoxazole/Trimethoprim Resistance in Community-Onset Urinary Tract Infections
  77. Erratum
  78. 2733. Association Between Influenza Vaccination Coverage and Ambulatory Antibiotic Prescription Rates in Children in South Carolina
  79. 122. Evaluation of Early Clinical Failure Criteria in Patients with Enterococcus Species Bloodstream Infection
  80. 851. Validation of Quick Pitt Bacteremia Score in Patients with Staphylococcus aureus Bloodstream Infection
  81. Direct Measurement of Performance: A New Era in Antimicrobial Stewardship
  82. COPD Exacerbations — A Target for Antibiotic Stewardship
  83. Seasonal variation in antimicrobial resistance rates of community-acquired Escherichia coli bloodstream isolates
  84. Resilience of the Pitt Bacteremia Score: Three Decades and Counting
  85. Syndrome-specific versus prospective audit and feedback interventions for reducing use of broad-spectrum antimicrobial agents
  86. Oral antibiotics for uncomplicated and complicated bloodstream infections
  87. Evaluation of early clinical failure criteria for gram-negative bloodstream infections
  88. A Baker’s Dozen of Top Antimicrobial Stewardship Publications in 2016
  89. Association Between Body Mass Index and Mortality in Patients With Gram-Negative Bloodstream Infections
  90. Derivation of a quick Pitt bacteremia score to predict mortality in patients with Gram-negative bloodstream infection
  91. Utility of Combination Antimicrobial Therapy in Adults with Bloodstream Infections due to Enterobacteriaceae and Non-Fermenting Gram-Negative Bacilli Based on In Vitro Analysis at Two Community Hospitals
  92. 645
  93. Bloodstream Infection due to Piperacillin/Tazobactam Non-Susceptible, Cephalosporin-Susceptible Escherichia coli: A Missed Opportunity for De-Escalation of Therapy
  94. 475. Burden of Clostridium difficile Infection in South Carolina: A Population-Based Study
  95. 1043. Evaluation of Early Clinical Failure Criteria for Gram-Negative Bloodstream Infections
  96. 975. Clostridium difficile Infection and Antibiotic Prescription Rates in the Community: Explaining the Gender Gap
  97. Early de-escalation of antimicrobial therapy reduces risk of C. difficile infection
  98. Minimum Acceptable Susceptibility of Empirical Antibiotic Regimens for Gram-Negative Bloodstream Infections
  99. Ignoring the Elephant: Does the Infectious Diseases Society of America Support Sepsis-3 or Pre-sepsis Criteria?
  100. Risk factors for pneumonia due to beta-lactam-susceptible and beta-lactam-resistant Pseudomonas aeruginosa: a case–case–control study
  101. Reply to comments: duration of antimicrobial therapy for Gram-negative bacteremia secondary to urinary source of infection
  102. Duration of Antimicrobial Therapy for Enterobacteriaceae Bacteremia: Using Convenient End Points for Convenient Conclusions
  103. Got penicillin allergy? Carbapenems are not the answer
  104. A Global Declaration on Appropriate Use of Antimicrobial Agents across the Surgical Pathway
  105. Combination antimicrobial therapy for gram-negative bloodstream infections?
  106. Erratum to: Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA)
  107. The Global Alliance for Infections in Surgery: defining a model for antimicrobial stewardship—results from an international cross-sectional survey
  108. Development of Institutional Guidelines for Management of Gram-Negative Bloodstream Infections: Incorporating Local Evidence
  109. The Magic Formula: Optimizing Care While Using Less Broad-Spectrum Antibiotics
  110. For Bloodstream Infections: Optimize, Do Not Minimize
  111. Prediction of fluoroquinolone resistance in patients with complicated urinary tract infections
  112. When to use empirical anti-pseudomonal therapy?
  113. Microbiologic Predictors of Pelvic Osteomyelitis Related to Decubitus Ulcers
  114. Microbiology of Vertebral Osteomyelitis and Implications on Empiric Therapy
  115. A Simplified Pitt Bacteremia Score (qPitt) to Predict Mortality in Patients with Gram-negative Bloodstream Infection
  116. The ESBL Prediction Score
  117. Non-tuberculous mycobacterial bloodstream infections in patients with indwelling vascular catheters – the role of sickle cell anaemia
  118. Association between chronic hemodialysis and bloodstream infections caused by chromosomally mediated AmpC-producing Enterobacteriaceae
  119. Effectiveness of oral antibiotics for definitive therapy of Gram-negative bloodstream infections
  120. Association between inappropriate empirical antimicrobial therapy and hospital length of stay in Gram-negative bloodstream infections: stratification by prognosis
  121. Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA)
  122. Comparison of ß-lactam plus aminoglycoside versus ß-lactam plus fluoroquinolone empirical therapy in serious nosocomial infections due to Gram-negative bacilli
  123. Prediction of Fluoroquinolone Resistance in Gram-Negative Bacteria Causing Bloodstream Infections
  124. Validation of Fluoroquinolone Resistance Score in Patients With Complicated Urinary Tract Infections
  125. Optimal Duration of Antimicrobial Therapy for Bloodstream Infections Due to Gram-Negative Bacilli
  126. Impact of fluoroquinolone resistance in Gram-negative bloodstream infections on healthcare utilization
  127. Osteomyelitis After Open Fractures Adjusting Prophylactic Antimicrobial Therapy
  128. Effectiveness of Oral Antibiotics for Definitive Therapy of Gram-Negative Bloodstream Infections
  129. Prediction of Fluoroquinolone Resistance in Patients With Gram-Negative Bloodstream Infection
  130. Combination Versus Monotherapy for Gram-Negative Bloodstream Infections: Matching by Predicted Prognosis
  131. Association Between Inappropriate Empirical Antimicrobial Therapy and Hospital Length of Stay in Gram-Negative Bloodstream Infections
  132. Antimicrobial Stewardship and Rapid Diagnostic Testing Bundle for Local Management of Gram-Negative Bloodstream Infections
  133. Bloodstream Infections and Central Line–Associated Bloodstream Infections
  134. Antibiotics save lives
  135. External validation of bloodstream infection mortality risk score in a population-based cohort
  136. 715Impact of Fluoroquinolone Resistance on Community-Onset Gram-Negative Bloodstream Infections
  137. 225Development of Institutional Guidelines for Management of Gram-Negative Bloodstream Infections: Incorporating Local Evidence
  138. 1705Non-Tuberculous Mycobacterial Bloodstream Infections in Patients with In-Dwelling Vascular Access Catheters- Role of Sickle Cell Disease
  139. Community-acquired Methicillin-resistant Staphylococcus aureus Prostatic Abscesses
  140. Predictive scoring model of mortality in Gram-negative bloodstream infection
  141. Asthma and risk of non-respiratory tract infection: a population-based case–control study
  142. Temporal Trends, Clinical Characteristics, and Outcomes of Histoplasmosis in a Tertiary Care Center in Kentucky, 2000 to 2009
  143. Overall burden of bloodstream infection and nosocomial bloodstream infection in North America and Europe
  144. Asthma and Risk of Community-Acquired Blood Stream Infection Caused by Escherichia Coli: A Population-Based Case-Control Study
  145. Asthma and Severity of Blood Stream Infection Caused by Escherichia coli: A Population-Based Study
  146. Impact of healthcare-associated acquisition on community-onset Gram-negative bloodstream infection: a population-based study
  147. Impact of Gram-Negative Bloodstream Infection on Long-Term Allograft Survival After Kidney Transplantation
  148. Temporal trends in Enterobacter species bloodstream infection: a population-based study from 1998–2007
  149. Cefepime effectiveness in Gram-negative bloodstream infections
  150. Influence of referral bias on the clinical characteristics of patients with Gram-negative bloodstream infection
  151. Epidemiology and outcome of Gram-negative bloodstream infection in children: a population-based study
  152. Recurrent gram-negative bloodstream infection: A 10-year population-based cohort study
  153. Bacteremia complicating gram-negative urinary tract infections: A population-based study
  154. Epidemiology and Outcome of Klebsiella Species Bloodstream Infection: A Population-Based Study
  155. Are E. coli infections more common in the summer?
  156. Antimicrobial resistance trends of Escherichia coli bloodstream isolates: a population-based study, 1998-2007
  157. Incidence Rate and Outcome of Gram-Negative Bloodstream Infection in Solid Organ Transplant Recipients
  158. β-Lactam and Fluoroquinolone Combination Antibiotic Therapy for Bacteremia Caused by Gram-Negative Bacilli
  159. Incidence of Pseudomonas aeruginosa Bacteremia: A Population-Based Study
  160. Invasive Enteric Infections in Hospitalized Patients With Underlying Strongyloidiasis